Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Price

Showing results (101-110 of 153) with videos related to

Pageof 16
Sort By:
Acta Oncologica (Stockholm, Sweden)|February 6, 2014
The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Dirkje W Sommeijer, Christos S Karapetis, John R Zalcberg, et al.
Journal of Public Health (Oxford, England)|March 6, 2026
A multicomponent, place-based approach to improving men's health and well-being in disadvantaged areas: a qualitative studyShelina Visram, Mabel Lie, Chris Haywood, et al.
Microorganisms|February 26, 2025
A Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis, and Breast CancerSima Kianpour Rad, Kenny K L Yeo, Fangmeinuo Wu, et al.
Clinical Colorectal Cancer|March 18, 2004
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinomaTimothy J Price, Paul J Ross, Tamas Hickish, et al.
The Lancet. Oncology|April 18, 2014
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyTimothy J Price, Marc Peeters, Tae Won Kim, et al.
Cancer Medicine|August 10, 2013
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumabTimothy J Price, Jennifer E Hardingham, Chee K Lee, et al.
International Journal of Cancer|December 31, 2013
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancerMaressa A Bruhn, Amanda R Townsend, Chee Khoon Lee, et al.
Internal Medicine Journal|January 28, 2020
Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer RegistryDavid McNeill, Christos S Karapetis, Timothy J Price, et al.
Expert Review of Anticancer Therapy|July 19, 2018
Targeted therapy for metastatic colorectal cancerTimothy J Price, Monica Tang, Peter Gibbs, et al.
The New Zealand Medical Journal|March 3, 2017
Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillanceSusan Parry, Randall W Burt, Aung Ko Win, et al.
Pageof 16

Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
Acta Oncologica (Stockholm, Sweden)|February 6, 2014
The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Dirkje W Sommeijer, Christos S Karapetis, John R Zalcberg, et al.
Journal of Public Health (Oxford, England)|March 6, 2026
A multicomponent, place-based approach to improving men's health and well-being in disadvantaged areas: a qualitative studyShelina Visram, Mabel Lie, Chris Haywood, et al.
Microorganisms|February 26, 2025
A Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis, and Breast CancerSima Kianpour Rad, Kenny K L Yeo, Fangmeinuo Wu, et al.
Clinical Colorectal Cancer|March 18, 2004
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinomaTimothy J Price, Paul J Ross, Tamas Hickish, et al.
The Lancet. Oncology|April 18, 2014
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyTimothy J Price, Marc Peeters, Tae Won Kim, et al.
Cancer Medicine|August 10, 2013
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumabTimothy J Price, Jennifer E Hardingham, Chee K Lee, et al.
International Journal of Cancer|December 31, 2013
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancerMaressa A Bruhn, Amanda R Townsend, Chee Khoon Lee, et al.
Internal Medicine Journal|January 28, 2020
Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer RegistryDavid McNeill, Christos S Karapetis, Timothy J Price, et al.
Expert Review of Anticancer Therapy|July 19, 2018
Targeted therapy for metastatic colorectal cancerTimothy J Price, Monica Tang, Peter Gibbs, et al.
The New Zealand Medical Journal|March 3, 2017
Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillanceSusan Parry, Randall W Burt, Aung Ko Win, et al.
Pageof 16